Sponsors (22)
The bill sustains and modestly increases federal support for cord blood/stem‑cell inventory through FY2027–2031—improving patient access and program stability—while increasing potential federal costs and giving the Secretary broad discretion that could lead to unit transfers/discards and uncertainty for smaller banks and clinicians.
Patients who need stem-cell transplants could get access to better‑matched, more clinically useful cord blood inventory because the Secretary can size and shape the inventory based on current science.
The bill provides multi‑year program authorization and maintains federal support through FY2027–2031, giving HHS, state public‑health agencies, and hospitals greater planning and staffing certainty and an increased annual authorization level for program activities.
Cord blood banks that meet updated standards get clearer criteria for funding and contracts, which can improve resource use and promote longer‑term program stability for collection and storage activities.
Authorization of higher annual funding does not guarantee Congress will appropriate the authorized amounts, so programs may still face funding uncertainty despite the multi‑year authorization.
Some existing stored cord blood units could be discarded or transferred under the new authorities, meaning families and donors may lose access to specific banked units they expected to remain available.
Smaller or nonoperational cord blood banks could lose units, contracts, or funding, reducing local collection capacity and access to cord blood in some communities.
Based on analysis of 3 sections of legislative text.
Reauthorizes and raises authorized funding for stem cell programs and replaces a numeric cord-blood inventory target with Secretary-determined sufficiency and inventory-management authority.
Reauthorizes and adjusts funding for the federal stem cell transplantation and cord blood programs, keeping the existing $31,009,000 annual authorization and adding a new $33,009,000 annual authorization for fiscal years 2027–2031. It also replaces a fixed numeric target for the National Cord Blood Inventory with a Secretary-determined sufficiency standard and gives the Secretary more explicit authority to manage inventory size, composition, transfers, and disposition of units based on scientific, clinical, and operational factors. The bill requires contract decisions to consider current scientific and clinical information, defines “high-quality cord blood unit” to include industry and FDA standards, authorizes transfers from nonoperational or noncompliant banks, and extends program authorizations through FY2027–2031. These changes aim to make inventory management more flexible and science-driven while continuing federal support for cord blood and stem cell transplantation programs.
Official title: Stem Cell Therapeutic and Research Reauthorization Act of 2025
Introduced September 4, 2025 by Christopher Henry Smith · Last progress July 21, 2026